RxDoctor Payments Data

Matthew Way, MD

Psychiatry · Richmond, VANPI 1841518008

Payments from drug & device makers

$1,466in general payments, 2019–2025

Across 101 payments — averaging $14.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$312
  • Otsuka America Pharmaceutical, Inc.$231
  • Teva Pharmaceuticals USA, Inc.$158
  • Johnson & Johnson$155
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$138
  • Avanir Pharmaceuticals, Inc.$126
  • plus $345 from 8 others

What the payments were for

  • Speaking & faculty fees$141%
  • Food & beverage$1,30589%
  • Education$14710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,466 in reported general payments places this provider in the 75th percentile of 884 psychiatry providers in Virginia.

See all psychiatry providers in Virginia

Medicare billing

Part B allowed, 2024
$23,843
Medicare patients
43
Services billed
332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyvanseLisdexamfetamine Dimesylate19$7,565
Desvenlafaxine Succinate ErDesvenlafaxine Succinate22$2,163
Quetiapine Fumarate45$1,719
Lamotrigine113$1,508
Atomoxetine Hcl16$1,442
Buspirone Hcl68$1,437
Duloxetine Hcl38$1,242
Clozapine23$1,231
Amitriptyline Hcl46$853
Aripiprazole41$811
Temazepam11$805
Mirtazapine18$677
Methylphenidate Hcl32$657
Prazosin Hcl32$587
Venlafaxine Hcl ErVenlafaxine Hcl23$582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$15$7,56519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 884 psychiatry providers in Virginia.

Other psychiatry in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →